Records containing: Sickle Cell Disorders

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2026-02-05
  A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
• CLINICAL_TRIALS study record update · 2024-05-13
  A Phase II Stratified Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With Sickle Cell Disease With no Available Sibling Donor
• CLINICAL_TRIALS study record update · 2024-04-12
  Genomics and Personalized Medicine for All Though Artificial Intelligence in Haematological Diseases
• CLINICAL_TRIALS study record update · 2021-04-01
  An Open-Label 12-Week Food Study to Assess the Safety, Tolerability, And Physiological Effects of An Amino Acid Food Product, AXA4010, In Subjects With Sickle Cell Disease.
• CLINICAL_TRIALS study record update · 2021-02-10
  An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2015-03-18
  A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease
• CLINICAL_TRIALS study record update · 2013-10-28
  A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease
• CLINICAL_TRIALS study record update · 2013-08-19
  A Multi-center, Randomized, Double Blind, Dose Escalation Safety Study of MP4CO in Clinically Stable Adult Sickle Cell Patients
• CLINICAL_TRIALS study record update · 2013-06-19
  A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease